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Abstract: Serum methylmalonic acid (MMA) is elevated in vitamin B-12 deficiency and in kidney
dysfunction. Population reference values for serum MMA concentrations in post-folic acid
fortification period are lacking. Aims of this study were to report the population reference values
for serum MMA and to evaluate the relation between serum MMA and sex, age, race-ethnicity,
kidney dysfunction and vitamin B-12. We used data from three National Health and Nutrition
Examination Surveys, 1999–2000, 2001–2002 and 2003–2004 conducted after folic acid fortification
commenced (n = 18,569). Geometric mean MMA was≈22.3% higher in non-Hispanic white compared
to non-Hispanic black (141.2 vs. 115.5 nmol/L) and was ≈62.7% higher in >70 years old persons
compared to 21–30 years old persons (196.9 vs. 121.0 nmol/L). Median serum MMA was ≈28.5%
higher in the 1st the quartile of serum vitamin B-12 than in the 4th quartile of serum vitamin B-12 and
was ≈35.8% higher in the 4th quartile of serum creatinine than in the 1st quartile of serum creatinine.
Multivariate-adjusted serum MMA concentration was significantly associated with race-ethnicity
(p < 0.001) and age (p < 0.001) but not with sex (p = 0.057). In this large US population based
study, serum MMA concentrations presented here reflect the post-folic acid fortification scenario.
Serum MMA concentrations begin to rise at the age of 18–20 years and continue to rise afterwards.
Age-related increase in serum MMA concentration is likely to be due to a concomitant decline in
kidney function and vitamin B-12 status.
Keywords: age; cobalamin; creatinine; MMA; methylmalonic acid; NHANES; National Health and
Examination Survey; race-ethnicity; reference values; vitamin B-12
1. Background
Serum methylmalonic acid (MMA) concentrations are elevated in vitamin B-12 deficiency. It is
derived from L-methylmalonyl CoA due to impaired function of L-methylmalonyl CoA mutase [1].
L-methylmalonyl CoA mutase requires adenosylcobalamin, a coenzyme of vitamin B-12, which
converts L-methlymalonyl CoA to succinyl CoA [2,3]. MMA interferes with energy production
in mitochondria by inhibiting succinate dehydrogenase, an electron transport protein complex II [4].
Thus, the elevated MMA may have negative effect on health. It has been reported that elevated MMA
may be detrimental to the nervous system and kidney [5].
Although serum vitamin B-12 concentrations are used to assess the nutritional status of
vitamin B-12 [6], serum vitamin B-12 may not reflect true vitamin B-12 status because some individuals
with low-normal serum vitamin B-12 exhibit tissue vitamin B-12 deficiency [7]. Vitamin B-12 circulates
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bound to holotranscobalamin (holoTC) (6–20%) and haptocorrin. Only the vitamin B-12 attached
to holoTC, a biologically active vitamin B-12, is capable of delivering vitamin B-12 to the tissues.
Although separate biological assay is available for measuring the holoTC, commonly used vitamin
B-12 assays measures the total vitamin B-12 (holoTC B12 and haptocorrin B12). Because of this
limitation, serum MMA is regarded as a reliable marker of vitamin B-12 deficiency in those with
normal renal function [7].
Morris et al. [8], using data collected in the pre-folic acid fortification period (1991–1994) reported a
≈20% prevalence of high serum MMA in older Americans. There are some concerns that increased folic
acid intake as a result of folic acid fortification efforts in the US has adversely affected the vitamin B12
status [9]. Using the post-folic acid fortification data Selhub et al. [9] reported that high folate in vitamin
B-12 deficient individuals negatively affected methlymalonyl CoA mutase and methionine synthase
activities leading to increased MMA and total homocysteine (tHcy) concentrations, respectively. Also,
Morris et al. reported [10] that high folate status in those with low vitamin B-12 status was related to
anemia and cognitive impairment.
Previous reports on MMA concentrations were based on either small convenience sample or
non-representative US population [11–13]. In this study, we used data reported in three nationally
representative sample surveys, National Health and Nutrition Examination Surveys (NHANES)
1999–2000, 2001–2002 and 2003–2004 and derived population-based reference values. By combining
three surveys into one analytic data, yielded a large sample size and increased the precision of the
serum MMA estimate.
In this report, we presented reference values for serum MMA concentrations and the associations
between serum MMA and sex, age, race-ethnicity, serum creatinine, a measure of kidney function and
serum vitamin B-12 in the post-folic acid fortification period, 1999–2004 for US adolescents and adults.
2. Methods
2.1. Description of Survey and Study Sample
National Center for Health Statistics (NCHS) conducts National Health and Nutrition Examination
Surveys (NHANES) on a periodic basis. NHANES was designed to be a complex, stratified, multi-stage
probability sample survey. As part of the household interview, demographic, socioeconomic, dietary
and health related data were collected in the participants’ home. A physician administered examination
was conducted on household interviewed persons in Mobile Examination Centers (MEC). Also, blood
and urine samples were collected in MEC for biochemical analyses. Certain populations such as young
children, older persons, non-Hispanic black and Hispanic/Mexican were over sampled to yield reliable
estimates for these groups. All NHANES protocols were approved by the NCHS Institutional Review
Board and survey participants signed informed consent before participating in NHANES.
Beginning 1999, NHANESs were conducted as continuous, annual surveys rather than the
periodic surveys. Briefly, NHANES 1999–2000 was conducted between March 1999 and December
2000 on 9965 individuals (all were home interviewed; 9282 were examined in MECs); NHANES
2001–2002 was conducted between January 2001 and December 2002 on 11,039 individuals (all were
home interviewed; 10,477 were examined in MECs); and NHANES 2003–2004 was conducted between
January 2003 and December 2004 on 12,761 individuals (10,122 were home interviewed; 9643 were
examined in MECs). In this study, NHANES 1999–2000 [14], NHANES 2001–2002 [15] and NHANES
2003–2004 [16] were concatenated into one analytic database (NHANES 1999–2004) as per NCHS
guidelines. A detailed description of these surveys has been reported earlier [17–19].
In the data analysis, individuals who reported their race-ethnicity as “unknown” or other than
non-Hispanic white, non-Hispanic black, or Hispanic/Mexican were excluded due to small sample size.
Also, individuals with missing values for sex, race-ethnicity, age, serum creatinine, serum vitamin B-12
and serum MMA were excluded from the data analysis. After applying the above exclusion criteria,
the final study sample consisted of 18,569 aged ≥ 12 years. Of those, men were ≈49% (n = 9020),
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women were ≈51% (n = 9549), non-Hispanic white were ≈44% (n = 8170), non-Hispanic black were
≈23% (n = 4351), Hispanic/Mexican were ≈33% (n = 6048), adolescents (12 to <18 years) were ≈24%
(n = 4546) and elderly persons (>60 years) were ≈23% (n = 4190). About 41% of the study participants
reported use of supplements (Table 1).
Table 1. Characteristics of study population: National Health and Nutrition Examination Survey
(NHANES), 1999–2004 1.
Characteristic
Men Women
p-Value 2
(n = 9020) (n = 9549)
Race-ethnicity
Non-Hispanic white, n, (%) 3971 (48.9) 4199 (51.1) 0.023
Non-Hispanic black, n, (%) 2140 (45.2) 2211 (54.8) <0.0001
Hispanic/Mexican, n, (%) 2909 (49.7) 3139 (50.3) 0.72
Age (year)
12–14, n (%) 1125 (51.1) 1187 (48.9) 0.41
15–17 years, n (%) 1178 (51.4) 1056 (48.6) 0.30
18–40 years, n (%) 2775 (49.7) 3328 (50.3) 0.63
41–65 years, n (%) 2254 (49.1) 2274 (50.9) 0.16
>65 years, n (%) 1590 (42.6) 1598 (57.4) <0.0001
Supplements use 3
Yes, n (%) 3222 (42.9) 4459 (57.1) <0.0001
No, n (%) 5798 (54.3) 5090 (45.7) <0.0001
Serum creatinine, µmol/L (mean
± SE) 83.4 ± 0.5 64.7 ± 0.4 <0.001
Serum vitamin B-12, pmol/L
(mean ± SE) 380.8 ± 7.0 418.5 ± 17.1 0.04
1 NHANES 1999–2000, 2001–2002 and 2003–2004, conducted after the folic acid fortification commenced, were
combined into one analytic data set, 1999–2004. n = 18,569. Weighted n = 204,316,278. Percentages in parentheses
are based on weighted sample size. 2 Significance between men and women. Rao-Scott χ2 test or unpaired t-test.
3 Persons who took vitamin/mineral supplements one month prior to the survey.
2.2. Measurements
Data were collected on body measurements, demography, physical function, health condition,
lifestyle behaviors, biochemical measurements of blood and urine and diet intake. Blood was collected
from venipuncture in the MECs according to the standard protocols. MMA was measured in serum
with gas chromatography/mass spectrophotometry. Vitamin B-12 was measured in serum with
Quantaphase II radioassay kit (Biorad Laboratories, Hercules, CA, USA). Serum creatinine was
measured using an autoanalyzer (Hitachi Model 917, Holliston, MA, USA, for NHANES 1999–2002;
Beckman Synchron LX20, Brea, CA, USA, for NHANES 2003–2004). Detailed methodology is described
elsewhere [20–22].
2.3. Statistical Analysis
As per NCHS’s guidelines, we used SUDAAN statistical software for Windows (SAS-Callable,
version 10.0, Research Triangle Institute, Research Triangle Park, NC, USA) to account for complex
survey design, differential probabilities of selection, non-coverage and non-response bias, sample
weights, primary sampling units and stratification variables in the data analysis. Also, SAS (SAS for
Windows, version 9.1, SAS Institute Inc., Cary, NC, USA) was used to manage and analyze data files.
In NHANES, 1999–2004, individuals whose age was ≥85 years were categorized as 85 years to
protect the confidentiality of survey participants. This precluded us using the age as a continuous
variable. In the data analysis, age was categorized into 19–30 years, 31–40 years, 41–50 years,
51–60 years, 61–70 years and >70 years old age groups. Standard errors were estimated with
Taylor Linearization method because this procedure takes NHANES’s complex survey design into
consideration. Cutoff values for 5th, 25th, 50th, 75th and 95th percentiles and arithmetic and geometric
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means for serum MMA concentrations were determined for sex, race-ethnicity, age, serum creatinine
and serum vitamin B-12. Also, sex-, race-ethnicity-, age, serum creatinine- and serum vitamin
B-12-specific serum MMA concentrations were determined with analysis of covariance. Because
serum MMA concentrations were skewed, a natural logarithmic transformation was applied to satisfy
the requirement for normality.
Additionally, we performed a sub group analysis on adult population (19 years or older) to
determine the prevalence of serum MMA for <100 nmol/L, 100 ≤ 200 nmol/L, 200 ≤ 300 nmol/L
and ≥300 nmol/L concentrations by race-ethnicity (non-Hispanic white, non-Hispanic black and
Hispanic/Mexican) and age. Age was categorized into 19–30 years, 31–40 years, 41–50 years, 51–60
years, 61–70 and ≥71 years old groups. Statistical significance was set at p < 0.05 in all analyses.
3. Results
Population reference values (geometric means, medians and 5th to 95th percentiles) for serum
MMA concentrations by sex, race-ethnicity, age, serum creatinine and serum vitamin B-12 for US
population in the post-folic acid fortification period are presented in Table 2. Mean, median and 5th
to 95th percentiles were higher for non-Hispanic white compared to non-Hispanic black, or Mexican
American/Hispanic, higher for elderly persons compared to adolescents or young adults, higher for
4th quartile serum creatinine compared to 1st quartile serum creatinine category and higher for 1st
quartile serum vitamin B-12 compared to 4th quartile serum vitamin B-12 category.
Table 2. Population reference values for serum methylmalonic acid (MMA) concentrations in the US
population: data from the National Health and Nutrition Examination Survey, 1999–2004 1.
n Mean± SE 2 Percentiles
5th 25th 3 50th 75th 95th
MMA, nmol/L
All subjects 18,569 155.0 ± 2.1 69.6 99.4 129.3 169.4 297.0
Sex
Men 9020 157.2 ± 2.6 70.0 100.0 129.7 169.8 299.2
Women 9549 152.9 ± 2.9 69.4 97.4 125.6 167.7 289.7
Race-ethnicity
Non-Hispanic white 8170 162.1 ± 2.4 79.0 106.3 134.4 179.1 300.0
Non-Hispanic black 4351 133.3 ± 8.1 59.8 83.5 109.1 139.5 229.9
Hispanic/Mexican 6048 135.7 ± 2.9 60.0 89.4 109.9 149.5 269.8
Supplement use 4
Yes 7681 155.3 ± 3.2 69.8 99.5 129.4 169.2 281.4
No 10,888 154.6 ± 2.4 69.4 99.3 129.2 169.7 301.9
Age (year)
12–14 2312 130.0 ± 2.6 69.5 89.9 116.8 149.4 226.1
15–17 2234 135.8 ± 6.0 65.9 89.3 109.8 139.9 227.3
18–40 6103 134.1 ± 1.7 69.0 89.8 119.2 150.0 248.7
41–65 4732 152.4 ± 2.8 73.3 100.3 129.6 169.5 274.8
>65 3188 236.1 ± 9.4 89.8 129.6 169.4 229.9 476.4
Serum creatinine 5 (µmol/L)
<55.96 5477 132.9 ± 1.7 59.9 89.3 109.8 149.3 254.7
55.96 ≤ 70.71 4106 146.4 ± 2.7 69.5 99.0 128.3 159.9 262.2
7.71 ≤ 79.8 4870 147.1 ± 2.7 72.3 99.7 129.0 160.1 272.6
≥79.8 4116 190.6 ± 6.3 79.6 112.5 149.1 199.6 377.7
Serum vitamin B-12 5 (pmol/L)
<260.96 4087 202.3 ± 6.1 79.4 110.0 149.7 209.7 428.0
260.96 ≤ 340.94 4363 146.6 ± 1.6 69.9 99.9 129.7 169.4 269.4
340.94 ≤ 445.91 4754 138.3 ± 2.9 69.4 97.6 119.7 152.0 240.0
≥445.91 5365 133.0 ± 2.5 68.1 89.7 116.5 149.3 232.5
1 Same as Table 1. 2 Values are geometric means ± standard error of geometric means. 3 Medians. 4 Persons who
took vitamin/mineral supplements one month prior to the survey. 5 Categorized into quartiles.
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Sex- and race-ethnicity-specific and age-specific geometric mean MMA concentrations for
US population in the post-folic acid fortification period are presented in Figures 1 and 2,
respectively. Geometric mean MMA concentration in non-Hispanic white (141.2 nmol/L) was
≈22.3% higher compared to non-Hispanic black (115.5 nmol/L) and was ≈18.5% higher compared to
Hispanic/Mexican (119.2 nmol/L). Older adults (>70 years old) had ≈62.7% higher (196.9 nmol/L)
geometric mean serum MMA compared to younger persons (21–30 years old) (121.0 nmol/L). In the
adjusted analysis, race-ethnicity (p < 0.001) and age (p < 0.001) but not sex (p = 0.057) were significantly
associated with serum MMA concentrations.
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Figure 1. Adjusted sex and race-ethnicity-stratified geometric mean concentrations of serum
methylmalonic acid ( A) in ≥12 years old persons in the US (n = 18,569). National Health and
utrition Exa ination Surveys 1999–2000, 2001–2002 and 2003–2004, conducted after the folic acid
fortification co enced, ere co bined into one analytic data set, 1999–2004. Values for en and
o en ere adjusted for race-ethnicity, age, supple ent use, seru creatinine and seru vita in
B-12. alues for race-ethnicity were adjusted for sex, age, supplement use, serum creatinine and serum
vita in B-12. Adjusted serum MMA concentrations were not significantly different between men and
wome (p < 0.11). Adjusted serum MMA concentratio s were significantly different between three
races (p < 0.001). Analysis w s performed on log serum MMA concentrations to satisfy normality.
Serum MMA concentrations for US population according to serum creatinine concentrations
and serum vitamin B12 concentrations in the post-folic acid fortification period are presented in
Figures 3 and 4, respectively. Not surprisingly, persons in the ≥90th percentile for serum creatinine
concentrations had the highest serum MMA concentrations while the persons in the <10th percentile
for serum creatinine had the lowest serum MMA concentrations. As expected, persons in the ≥90th
percentile for serum vitamin B12 concentrations had the lowest serum MMA concentrations, while the
persons in the <10th percentile for serum vitamin B12 had the highest serum MMA concentrations.
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(MMA) for ≥12 years persons in the US (n = 18,569). Serum MMA concentrations were adjusted for 
sex, race-ethnicity, age, supplement use and serum creatinine. Analysis was performed on log MMA 
concentrations to satisfy normality. 
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Figure 4. Serum vitamin B-12 stratified geometric mean concentrations of serum methylmalonic acid
( ) for 12 years old persons in the US (n = 18,569). Serum MA concentrations were adjusted for
sex, race-ethnicity, age, supple ent use and seru creatinine. Analysis was performed on log MMA
concentrations to satisfy nor ality.
Prevalence (%) of serum MMA concentrations in non-Hispanic white, non-Hispanic black and
Hispanic/Mexican by age (19 years or older) were presented in Table 3. Across all age groups,
the prevalence of low serum MMA (<100 nmol/L) were lower in non-Hispanic white compared to
non-Hispanic black, while the prevalence of high serum MMA (≥300 nmol/L) were higher in Hispanic
white compared to non-Hispanic black. In non-Hispanic white in comparison with non-Hispanic
black, the prevalence of high serum MMA (≥300 nmol/L) was almost double in 50 years and older
age group. Whereas the prevalence for Hispanic/Mexican were either close to non-Hispanic white or
in between non-Hispanic white and non-Hispanic black.
Table 3. Prevalence (%) of serum methylmalonic acid (MMA) concentrations in non-Hispanic white,
non-Hispanic black and Hispanic/Mexican by age: National Health and Nutrition Examination Survey,
1999–2004 1,2,3.
Age, Year ≤100 nmol/L 100≤ 200 nmol/L 200≤ 300 nmol/L ≥300 nmol/L
NW NB H/M NW NB H/M NW NB H/M NW NB H/M
19 3 ( 94 ) 26.8 50.0 40.2 59.6 47.0 5 .8 10.8 2.3 6.0 2.9 0.8 3.0
3 4 2008 23.9 43.5 0.0 4 1 48.7 51.0 .9 5.4 6.0 3.2 2.4 2.9
41–50 (n = 1929) 19.2 36.8 34.7 66.2 55.2 53.3 10.8 5.6 8.5 3.8 2.5 3.5
51–60 (n = 1516) 12.1 28.3 26.6 67.0 61.2 61.0 15.4 8.7 7.3 5.5 1.8 5.1
61–70 (n = 1684) 9.5 24.6 19.9 64.8 61.2 62.2 16.7 10.5 11.5 9.0 3.7 6.5
>70 (n = 2069) 3.9 4.8 8.9 50.3 56.2 55.1 27.1 28.5 17.5 18.7 10.4 18.6
1 Same as Table 1. n = 12,154. Sub-group analysis was performed on adult population only (age 19 years or older).
2 Abbreviations: NW, non-Hispanic white; NB, non-Hispanic black; H/M, Hispanic/Mexican. 3 Prevalence were
age-specific and race-specific.
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4. Discussion
In this study, we report the first data on reference values for serum MMA concentrations in the
post-folic acid fortification period utilizing the data from 3 nationally representative sample surveys of
US population (1999–2004). By combining NHANES 1999–2000, 2001–2003 and 2003–2004 cycles into
one NHANES 1999–2004 database resulted in a large sample size (n = 18,579) and thus increased the
precision of the serum MMA estimate. Because the data used in this study are based on the nationally
representative sample, these results can be applied to the population reported in this study.
Circulating MMA concentrations are elevated in tissue vitamin B-12 deficiency. However, there
are other factors which may affect serum MMA concentrations in humans such as kidney dysfunction,
metabolism of odd chain fatty acids and amino acids such as methionine, isoleucine and threonine,
intestinal bacteria [3] and genetic defects in methlymalonyl CoA mutase (mut 0 and mut-) [23]. It is
unknown to what extent these can affect MMA balance in humans. In addition to MMA, compounds
such as propionyl CoA and methyl citrate (formed from condensation of propionyl CoA and acetyl
CoA by citrate synthase) are accumulated. It is well recognized that vitamin B-12 deficiency has been
linked to neurological disorders such as myelopathy, neuropathy, depression and poor cognition [24–26].
The deleterious effects of vitamin B-12 deficiency on nervous system are attributed partly due to
decreased methylation and partly due to deleterious effects of elevated MMA, propionly CoA,
methylcitrate [1] and tHcy [27].
Serum vitamin B-12 is a major determinant of MMA concentrations. Several studies documented
serum vitamin B-12 concentrations in the US population. In the Framingham study, 8%, 16%
and 39% adults (26–83 years old) had plasma vitamin B-12 < 148, <185 and <258 pmol/L,
respectively [28]. In the Framingham elderly population (67–96 years), 40.5% (222 out of 548) had
serum vitamin B-12 < 258 pmol/L [11]. These studies were based on white population. In the Los
Angeles elderly people (>60 years, n = 725), 11.8% had vitamin B-12 < 140 pmol/L and 16.6% had high
MMA (>370–376 pmol/L) [13]. Morris et al. [8], using the data from the pre-folic acid fortification
period (phase 2 of NHANES III) in 1145 older persons (age ≥ 65 years) reported ≈18% and ≈16%
prevalence of serum high MMA (>370 nmol/L) in men and women, respectively. Thus, the existing
data on the prevalence of vitamin B-12 deficiency in the US vary depending on the type of population
studied and the criteria used to define the vitamin B-12 deficiency.
Serum MMA was generally stable at the age below 20 years but gradually increased afterward.
The upward trend in serum MMA has been observed after the age 40 years. Geometric mean of
serum MMA was ≈63% higher in elderly persons (>70 years) compared to those in the age group of
18–20 years. In a sub-group analysis, we found prevalence of high serum MMA in the older persons
compared to the younger persons regardless of their race-ethnicity (Table 3). This age-related increase
in serum MMA is caused by decreased kidney function [29] and increased prevalence of vitamin B-12
deficiency resulting from decreased vitamin B-12 absorption. The latter is caused by gastric atrophy
accompanied by a decreased secretion of acid and pepsin [30–32] needed to release the protein-bound
vitamin B-12 prior to its absorption. Use of medications by some elderly (e.g., as histamine H2 receptor
antagonists and proton pump inhibitors) might lead to achlorhydria [33] prompting malabsorption of
the protein-bound vitamin B-12 and thereby an elevated MMA.
Our data suggest that the race-ethnicity affect serum MMA concentration in the US. Non-Hispanic
whites had significantly higher serum MMA concentrations compared to non-Hispanic black or
Hispanic/Mexican in spite of higher use of vitamin/mineral supplements (56.7%) and a lower
prevalence of the elevated serum creatinine (2.1%), a surrogate marker of kidney dysfunction.
Additionally, we found by a sub-group analysis that non-Hispanic black have lower serum MMA
concentrations compared to the other two race-ethnicities studied (Table 3). In non-Hispanic
white compared to non-Hispanic black, the prevalence of high serum MMA (≥300 nmol/L) were
≈205%, ≈143% and ≈80% higher in 51–60 years old, 61–70 years old and >70 years old persons,
respectively. Although the prevalence of kidney dysfunction is higher in non-Hispanic black compared
to non-Hispanic white, the lower prevalence of high serum MMA in non-Hispanic black indicates
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that in this study kidney dysfunction is not a major factor in determining the serum MMA in older
non-Hispanic black.
Recently Malloy et al. [34] reported that single nucleotide polymorphism in 3-hydroxyisobutyryl
CoA hydrolase (HIBCH), is strongly associated with elevated MMA concentrations in Irish white
population. This newly identified enzymatic polymorphism is more likely explanation for elevated
MMA in whites compared to other race-ethnicities. This polymorphism influences the serum MMA
concentrations independently of vitamin B-12 status [34]. Other variants in genes that do not encode
vitamin B-12 metabolic genes (ASCF3, SUCLG1 and SUCLA) can also increase circulating MMA [35].
Additionally, it is possible that metabolic differences between race-ethnicities could contribute to the
differences in serum MMA between races. Morris et al. [8] using the data from elderly persons reported
high serum MMA in non-Hispanic white but the prevalence of high serum MMA in those subjects
was similar to non-Hispanic black. In contrast, Carmel et al. [13] observed significantly lower vitamin
B-12 concentrations in whites and Latin Americans compared to blacks. Nonetheless, the causes for
differences between races regarding vitamin B-12 metabolism needs further attention.
We found serum MMA concentrations increased with age especially after the age of 51–60 years.
Similarly, Risch et al. [36] in Swiss population (n = 1143) reported significant increment in MMA along
with increments of tHcy although vitamin B-12 and holoTC remained steady after the age 60 years.
This increased MMA in elderly persons can be attributed to impaired kidney function. In elderly
subjects (>71 years old), the metabolic vitamin B-12 deficiency was 30% compared to only 12% in
younger subjects (<50 years old) who were attending a stroke prevention clinic [37]. Although a
direct relation between serum creatinine, a surrogate marker of kidney function and serum MMA
concentrations exists, all cases of high MMA cannot be attributed to renal dysfunction in older adults.
It has been hypothesized that elevated MMA may damage the kidney [38]. It is not known whether
increased MMA causes impaired kidney function or impaired kidney function leads to elevated
MMA concentrations.
In comparison to pre-folic acid fortification period [39], we report elevated MMA in the post-folic
acid fortification period in all subjects (pre, 137 nmol/L vs. post, 155 nmol/L), men (pre, 141 nmol/L
vs. post, 157.2 nmol/L), women (pre, 133 nmol/L vs. post, 152.9 nmol/L). This further strengthens the
notion that increased folic acid intake in the post folic acid fortification period may have negatively
affected the vitamin B-12 status leading to increased circulating MMA concentrations. The possible
explanation for this phenomenon is that the high folate status in the post-folic acid fortification
period may have adversely affected the methylmalonyl CoA mutase enzyme leading to elevated
MMA [9]. Other unknown causes may have also contributed to elevated serum MMA in the
post-fortification period.
To date, there is no consensus defining a low vitamin B-12 status based on serum vitamin B-12
and MMA, because each marker has insufficient diagnostic specificity and sensitivity [40]. In some
cases, serum vitamin B-12 does not reflect vitamin B-12 nutritional status because only ≈6–20% is
bound to holoTC, which is a biologically active vitamin B-12 fraction, capable of delivering vitamin
B-12 to tissues whereas the remaining majority is bound to haptocorrin [41]. Recently, measurement of
holoTC has been suggested as a sensitive and early marker of vitamin B-12 deficiency [42]. However,
in a recent review by Golding [43] provided the evidence that holoTC concentration cannot be used as
a reliable and a sensitive marker of early vitamin B-12 deficiency any more than serum vitamin B-12
concentration because this concept is based on a faulty model for the diagnosis and staged development
of vitamin B-12 deficiency proposed by Herbert in 1980s. Further Golding [44] reported that holoTC
is much less sensitive than circulating MMA concentration. This fact is further corroborated by
Remacha et al. [45] in a study where holoTC concentrations were not decreased in 1/3 of the subjects
in spite of low vitamin B-12. In fact, holoTC concentrations were significantly reduced in 48% folate
deficient individuals and this decrease was not due to vitamin B-12 deficiency suggesting a role for
folate in holoTC metabolism.
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Although MMA appears to be a sensitive marker of vitamin B-12 deficiency, MMA concentrations
are elevated in some subjects with kidney dysfunction [29] and in patients with polymorphisms [34].
Like MMA, holoTC is also elevated in renal dysfunction [46] due to the decreased uptake by erythroid
cells. In contrast, decreased holoTC in serum could be the result of increased uptake of vitamin B-12
by erythroid cells [45]. Elevated tHcy is not specific to vitamin B-12 deficiency. Thus, there is no single
universal standard for the measurement of vitamin B-12 deficiency. Therefore, a multiple marker
approach has been proposed for the diagnosis of vitamin B-12 deficiency. Hermann et al. [46] proposed
a two-marker approach (serum holoTC and MMA concentrations). Recently, Fedosov et al. [47] derived
a novel systematic algorithm {(vitamin B-12 status) = log10[(holoTC × B12)/(MMA × Hcy)]–(age
factor)} for diagnosis of vitamin B-12 deficiency using four markers of vitamin B-12 status (serum
vitamin B-12, holoTC, MMA and tHcy concentrations). They proposed five grades of vitamin B-12
status, i.e., elevated vitamin B-12, vitamin B-12 adequacy, low B-12, possible vitamin B-12 deficiency
and probable vitamin B-12 deficiency based on the circulating concentrations of four biomarkers
of vitamin B-12 status. However, Fedosov et al.’s [47] approach is not applicable to children below
18 years of age and pregnant women.
5. Conclusions
In this large population study based on the data collected in the post-folic acid fortification era,
age, race-ethnicity, serum creatinine and serum vitamin B-12 are related to serum MMA concentrations.
Based on serum MMA concentrations across the age groups, serum MMA concentrations begin to
rise after the age 40 years, continue to rise afterwards and then steeply increase after the age 70 years.
Serum MMA utility as a gold standard for vitamin B-12 deficiency is limited in patients with normal
renal function and in younger persons.
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